Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL versus IOPAMIDOL 200 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL versus IOPAMIDOL 200 IN PLASTIC CONTAINER.
IOPAMIDOL vs IOPAMIDOL-200 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble radiographic contrast agent that attenuates X-rays by increasing the density of vascular structures and organs, thereby enhancing contrast in imaging studies. It does not have a pharmacological mechanism of action but exerts its effect via physical radiopacity.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing vascular and tissue contrast during imaging procedures.
Intravenous or intra-arterial administration; dose varies by procedure (e.g., cerebral angiography: 5-10 mL; coronary arteriography: 3-10 mL per injection; CT: 50-150 mL; adults: up to 200 mL total).
Intravascular administration: 1-2 mL/kg (200 mg I/mL) intravenously, up to a maximum of 150 mL per diagnostic procedure. Intraarterial administration: varies by procedure; typical 5-60 mL per injection.
None Documented
None Documented
Clinical Note
moderateIopamidol + Metformin
"The risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin."
2 hours; prolonged in renal impairment (up to 30 hours in anuria)
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function; prolonged in renal impairment.
Renal: >90% unchanged; biliary/fecal: <2%
Primarily renal (99% unchanged in urine within 24 hours). Biliary/fecal excretion <1%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent